FDA Approves Rybrevant for Certain Patients with Non-Small Cell Lung Cancer – Lung Cancer Blog
Lung cancer is a complex disease, accounting for almost 25% of all cancer deaths. The Food and Drug Administration (FDA) has approved Rybrevant for treatment of adults with non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations. This approval marks the first targeted treatment option available to
